Post-effective Amendment to an S-8 Filing (s-8 Pos)
17 3월 2022 - 5:02AM
Edgar (US Regulatory)
As filed with the Securities and Exchange Commission on March 16, 2022
Registration No. 333-263562
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST
EFFECTIVE
AMENDMENT NO. 1
TO
Form S-8
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
Ovid Therapeutics Inc.
(Exact name of registrant as specified in its charter)
|
|
|
| Delaware |
|
46-5270895 |
| (State or other jurisdiction of
incorporation or organization) |
|
(IRS employer
identification number) |
|
|
|
| 1460 Broadway, Suite 15044 |
|
|
| New York, New York |
|
10036 |
| (Address of Principal Executive Offices) |
|
(Zip Code) |
2017 Equity Incentive Plan
(Full title of the plan)
Jeremy M. Levin, DPhil, MB BChir
Chief Executive Officer
Ovid Therapeutics Inc.
1460 Broadway, Suite 15044
New York, New York 10036
(646) 661-7661
(Name, address, including zip code and telephone number, including area code, of agent for service)
Copies to:
|
|
|
| Thomas M. Perone
General Counsel and Secretary
Ovid Therapeutics Inc.
1460 Broadway, Suite 15044
New York, New York 10036
(646) 661-7661 |
|
Laura A. Berezin
Jaime L. Chase Cooley
LLP 3175 Hanover Street
Palo Alto, California 94304
(650) 843-5000 |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting
company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
| Large Accelerated Filer |
|
☐ |
|
Accelerated Filer |
|
☒ |
|
|
|
|
| Non-accelerated Filer |
|
☐ |
|
Smaller Reporting Company |
|
☒ |
|
|
|
|
|
|
|
|
Emerging growth company |
|
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒
PART I
EXPLANATORY NOTE
This Post-Effective
Amendment to Registration Statement on Form S-8 (this “Amendment”) is being filed solely to amend and restate the signature page of the Registration Statement on Form
S-8 filed with the Securities and Exchange Commission on March 15, 2022 (File
No. 333-263562) (the “Form S-8”) due to administrative error. The amended and restated signature page to the Form
S-8 immediately follows this explanatory note and immediately precedes the signature page to this Amendment.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York
on March 15, 2022.
|
|
|
| Ovid Therapeutics Inc. |
|
|
| By: |
|
/s/ Jeremy M. Levin, DPhil, MB BChir |
|
|
Jeremy M. Levin, DPhil, MB BChir |
|
|
Chief Executive Officer |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jeremy M. Levin, DPhil, MB BChir and
Jeffrey Rona, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and
in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection
therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform
each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has
been signed by the following persons in the capacities and on the dates indicated.
|
|
|
|
|
| Signature |
|
Title |
|
Date |
|
|
|
| /s/ Jeremy M. Levin, DPhil, MB
BChir Jeremy M. Levin, DPhil, MB BChir |
|
Chief Executive Officer and Director (Principal
Executive Officer) |
|
March 15, 2022 |
|
|
|
| /s/ Jeffrey Rona
Jeffrey Rona |
|
Chief Business and Financial Officer (Principal
Financial and Accounting Officer) |
|
March 15, 2022 |
|
|
|
| /s/ Karen Bernstein,
PhD Karen Bernstein PhD |
|
Director |
|
March 15, 2022 |
|
|
|
| /s/ Barbara Duncan
Barbara Duncan |
|
Director |
|
March 15, 2022 |
|
|
|
| /s/ Bart Friedman
Bart Friedman |
|
Director |
|
March 15, 2022 |
|
|
|
| /s/ Kevin Fitzgerald,
Ph.D. Kevin Fitzgerald, Ph.D. |
|
Director |
|
March 15, 2022 |
|
|
|
| /s/ Michael Poole, M.D.,
FACP Michael Poole, M.D., FACP |
|
Director |
|
March 15, 2022 |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York
on March 16, 2022.
|
|
|
| Ovid Therapeutics Inc. |
|
|
| By: |
|
/s/ Jeremy M. Levin, DPhil, MB BChir |
|
|
Jeremy M. Levin, DPhil, MB BChir |
|
|
Chief Executive Officer |
POWER OF ATTORNEY
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has
been signed by the following persons in the capacities and on the dates indicated.
|
|
|
|
|
| Signature |
|
Title |
|
Date |
|
|
|
| /s/ Jeremy M. Levin, DPhil, MB
BChir Jeremy M. Levin, DPhil, MB BChir |
|
Chief Executive Officer and Director (Principal
Executive Officer) |
|
March 16, 2022 |
|
|
|
| /s/ Jeffrey Rona
Jeffrey Rona |
|
Chief Business and Financial Officer (Principal
Financial and Accounting Officer) |
|
March 16, 2022 |
|
|
|
| *
Karen Bernstein PhD |
|
Director |
|
March 16, 2022 |
|
|
|
| *
Barbara Duncan |
|
Director |
|
March 16, 2022 |
|
|
|
| *
Bart Friedman |
|
Director |
|
March 16, 2022 |
|
|
|
| *
Kevin Fitzgerald, Ph.D. |
|
Director |
|
March 16, 2022 |
|
|
|
| *
Michael Poole, M.D., FACP |
|
Director |
|
March 16, 2022 |
|
|
|
| * By: |
|
/s/ Jeffrey Rona |
|
|
Jeffrey Rona |
|
|
Attorney-in-Fact |
Ovid Therapeutics (NASDAQ:OVID)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Ovid Therapeutics (NASDAQ:OVID)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
